Effect of montelukast for treatment of asthma in cigarette smokers

Slides:

Advertisements

Similar presentations

Does BCG vaccination protect against childhood asthma

Advertisements

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

The natural history of soy allergy

Fig. 3. Smoothed spline plot of percentage of days with asthma control by treatment group versus smoking history (in pack years; A) and FEV1 percent predicted.

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial Jens U. Ponikau, MD, David.

Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers Robert A. Wise,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

Physician needs in health informatics: Just ask the docs

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Does BCG vaccination protect against childhood asthma

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Reply Journal of Allergy and Clinical Immunology

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Roles of arginase variants, atopy, and ozone in childhood asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Phillip Lieberman, MD, David Golden, MD

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

What the asthma end points we know and love do and do not tell us

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Development and cross-sectional validation of the Childhood Asthma Control Test Andrew H. Liu, MD, Robert Zeiger, MD, Christine Sorkness, PharmD, Todd.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Advances in the approach to the patient with food allergy

Geographic variability in childhood asthma prevalence in Chicago

High prevalence of severe asthma in a large random population study

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Phillip Lieberman, MD, Richard A

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

George Philip, MD, Carolyn M

Eckard Hamelmann, MD, Eric D

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma: A randomized controlled trial Andrea J. Apter,

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Daniel Menzies, MBChB, Arun Nair, MBBS, Karen T

Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists Michael Schatz, MD, MS, Christine.

Negative affect, medication adherence, and asthma control in children

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Susan L. Janson, DNSc, Kelly Wong McGrath, BA, Jack K

Primary prevention of asthma and allergy

Presentation transcript:

Effect of montelukast for treatment of asthma in cigarette smokers David Price, MD, Todor A. Popov, MD, Leif Bjermer, MD, Susan Lu, PharmD, Romana Petrovic, MS, Kristel Vandormael, MS, Anish Mehta, BA, Jolanta D. Strus, MD, Peter G. Polos, MD, George Philip, MD Journal of Allergy and Clinical Immunology Volume 131, Issue 3, Pages 763-771.e6 (March 2013) DOI: 10.1016/j.jaci.2012.12.673 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 CONSORT diagram showing patient enrollment, randomization, discontinuation, completion, and inclusion of patients in analyses. FAS, Full analysis set. Journal of Allergy and Clinical Immunology 2013 131, 763-771.e6DOI: (10.1016/j.jaci.2012.12.673) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Distribution of percentage of days with asthma control by increments of 5%. Journal of Allergy and Clinical Immunology 2013 131, 763-771.e6DOI: (10.1016/j.jaci.2012.12.673) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Components of primary end point: percentage of days with asthma control during treatment. Journal of Allergy and Clinical Immunology 2013 131, 763-771.e6DOI: (10.1016/j.jaci.2012.12.673) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Primary and secondary endpoints over time. A, Percentage of asthma-control days (primary endpoint). B, Change from baseline in daytime asthma symptom score (0 to 6 scale). C, Change from baseline in morning peak expiratory flow (L/min). Journal of Allergy and Clinical Immunology 2013 131, 763-771.e6DOI: (10.1016/j.jaci.2012.12.673) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Smoothed spline plot of percentage of days with asthma control by treatment group versus smoking history (in pack years; A) and FEV1 percent predicted at baseline (B). Journal of Allergy and Clinical Immunology 2013 131, 763-771.e6DOI: (10.1016/j.jaci.2012.12.673) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions